These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24763264)

  • 1. Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo.
    Kallinen A; Todorov B; Kallionpää R; Bäck S; Sarparanta M; Raki M; García-Horsman JA; Bergström KA; Wallén EA; Männistö PT; Airaksinen AJ
    Eur J Med Chem; 2014 May; 79():436-45. PubMed ID: 24763264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitors.
    Jarho EM; Venäläinen JI; Poutiainen S; Leskinen H; Vepsäläinen J; Christiaans JA; Forsberg MM; Männistö PT; Wallén EA
    Bioorg Med Chem; 2007 Mar; 15(5):2024-31. PubMed ID: 17215128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Saario SM; Forsberg MM; Venäläinen JI; Paso HM; Männistö PT; Gynther J
    Bioorg Med Chem; 2002 Jul; 10(7):2199-206. PubMed ID: 11983517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prolyl oligopeptidase by Fmoc-aminoacylpyrrolidine-2-nitriles.
    Li J; Wilk E; Wilk S
    J Neurochem; 1996 May; 66(5):2105-12. PubMed ID: 8780042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformationally rigid N-acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Saarinen TJ; Jarho EM; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    Bioorg Med Chem; 2003 Aug; 11(17):3611-9. PubMed ID: 12901906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.
    Venäläinen JI; Juvonen RO; Garcia-Horsman JA; Wallén EA; Christiaans JA; Jarho EM; Gynther J; Männistö PT
    Biochem J; 2004 Sep; 382(Pt 3):1003-8. PubMed ID: 15217351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
    Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.
    Lawandi J; Toumieux S; Seyer V; Campbell P; Thielges S; Juillerat-Jeanneret L; Moitessier N
    J Med Chem; 2009 Nov; 52(21):6672-84. PubMed ID: 19888757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
    Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    J Med Chem; 2002 Sep; 45(20):4581-4. PubMed ID: 12238937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.
    Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT
    Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.
    Venäläinen JI; Juvonen RO; Forsberg MM; Garcia-Horsman A; Poso A; Wallen EA; Gynther J; Männistö PT
    Biochem Pharmacol; 2002 Aug; 64(3):463-71. PubMed ID: 12147298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules.
    Kánai K; Arányi P; Böcskei Z; Ferenczy G; Harmat V; Simon K; Bátori S; Náray-Szabo G; Hermecz I
    J Med Chem; 2008 Dec; 51(23):7514-22. PubMed ID: 19006380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.
    Goossens F; Vanhoof G; De Meester I; Augustyns K; Borloo M; Tourwe D; Haemers A; Scharpé S
    Eur J Biochem; 1997 Nov; 250(1):177-83. PubMed ID: 9432007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New prolyl oligopeptidase inhibitors developed from dicarboxylic acid bis(l-prolyl-pyrrolidine) amides.
    Wallén EA; Christiaans JA; Jarho EM; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    J Med Chem; 2003 Oct; 46(21):4543-51. PubMed ID: 14521416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
    Racys DT; Rea D; Fülöp V; Wills M
    Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.
    Myöhänen TT; Tenorio-Laranga J; Jokinen B; Vázquez-Sánchez R; Moreno-Baylach MJ; García-Horsman JA; Männistö PT
    Br J Pharmacol; 2011 Aug; 163(8):1666-78. PubMed ID: 21133893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
    Jansen K; Heirbaut L; Verkerk R; Cheng JD; Joossens J; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    J Med Chem; 2014 Apr; 57(7):3053-74. PubMed ID: 24617858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.